Abstract

A metal powder polymer composite sheet (200) is provided for use in additive layer manufacturing. The sheet (200) comprises a metal powder (202) and a polymer (201) that binds the metal powder together to form the sheet (200). The metal powder (202) consists of metal particles with a median aspect ratio of less than 0.8.

IPC Classes  ?

• B22F 10/20 - Direct sintering or melting
• B22F 1/06 - Metallic powder characterised by the shape of the particles
• B22F 1/10 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material
• B22F 12/50 - Means for feeding of material, e.g. heads
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 207/38 - 2-Pyrrolones
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 215/36 - Sulfur atoms
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 217/24 - Oxygen atoms
• C07D 221/18 - Ring systems of four or more rings
• C07D 231/18 - One oxygen or sulfur atom
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 277/36 - Sulfur atoms
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 307/64 - Sulfur atoms
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 333/34 - Sulfur atoms
• C07D 333/52 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems
• C07D 493/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• C07D 495/06 - Peri-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

A method for measuring an electron signal or an electron induced signal may be provided. The method may include providing a threshold number of events or a threshold event rate for a pixel on a detector. The method may include collecting from the detector the threshold number of events or determining that the threshold event rate is achieved, wherein a signal at the detector is an electron signal or an electron induced signal from a sample. The method may include modulating an intensity of an electron source directed to the sample in response.

IPC Classes  ?

• H01J 37/28 - Electron or ion microscopesElectron- or ion-diffraction tubes with scanning beams
• H01J 37/147 - Arrangements for directing or deflecting the discharge along a desired path
• H01J 37/22 - Optical or photographic arrangements associated with the tube
• H01J 37/244 - DetectorsAssociated components or circuits therefor

Abstract

A method for measuring an electron signal or an electron induced signal may be provided. The method may include providing a threshold number of events or a threshold event rate tor a pixel on a detector. The method may include collecting from the detector the threshold number of events or determining that the threshold event rate is achieved, wherein a signal at the detector is an electron signal or an electron induced signal from a sample. The method may include modulating an intensity of an electron source directed to the sample in response.

IPC Classes  ?

• H01J 37/244 - DetectorsAssociated components or circuits therefor
• H01J 37/28 - Electron or ion microscopesElectron- or ion-diffraction tubes with scanning beams

Goods & Services

Education and training services; entertainment; sporting and cultural activities; providing space for entertainment, sporting cultural and educational events; arrangement, conducting and organisation of exhibitions, events and conferences; arrangement, conducting and organisation of exhibitions, events and conferences that educate participants in the various aspects of the outcome of brain science and creativity and when they intersect; arrangement, conducting and organisation of exhibitions, events and conferences raising awareness of the relationship between brain health and creativity; arrangement, conducting and organisation of exhibitions, events and conferences raising awareness of the relationship between brain health and creativity which stimulates research into how creative practice might mitigate the negative effects of poverty, low education and disease on brain functioning and quality of life; educational services and information; educational examination; educational research; entertainment services and information; instruction and training services; presentation of live performances; providing museum facilities; provision of information on and access to education events; providing cultural facilities and educational facilities; organisation of competitions; providing recreation and cultural facilities and information; arranging and conducting of seminars, workshops and symposia; teaching and practical training; theatre productions; information relating to sporting, entertainment, cultural and educational activities; education, instruction and training provided on-line from a computer database or from facilities provided on the Internet and other similar information networks; organisation, production and presentation of on-line training and education provided on-line from a computer database or from facilities provided on the Internet and other similar information networks; translation services; advisory, consultancy and information services relating to the aforesaid.

Abstract

A fixation device for fastening to a native heart valve having native valve leaflets, the fixation device comprising: • (a) an expandable body, the expandable body having: (i) a collapsed configuration with a minimum cross-sectional area; (ii) a fully expanded configuration with a maximum cross-sectional area; and (iii) one or more intermediate configurations where the, or each, intermediate configuration has a cross-sectional area that is intermediate that of the collapsed configuration and that of the fully expanded configuration; • (b) a locking mechanism for locking the expandable body in at least one intermediate configuration; and • (d) at least one clamp on the expandable body, the clamp for engaging and holding a native valve leaflet.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

The invention relates to a method of immunotherapy for prevention or treatment of cancer in a subject, the method comprising the administration of an adjuvant, or administration of an adjuvant in combination with a tumour antigen, to the subject, wherein the adjuvant comprises polyglucosamine or acetylated polyglucosamine that comprises no more than 10% N-acetyl-D-glucosamine groups, and wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of two or more. The invention relates to a method of immunotherapy for solid-tumour cancer in a subject, the method comprising the administration of polyglucosamine or chitosan into the subject, wherein the administration is intratumoral and/or peritumoral.

IPC Classes  ?

• A61K 31/722 - ChitinChitosan
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

A method (Fig. 1) for separating a first layer from a second layer in a multilayer structure (a) is disclosed. The method comprises the step (b) of contacting the multilayer structure with a treatment solution comprising a solvent and a non-solvent until the first layer is separated from the second layer. The first layer comprises a polymer, wherein the polymer is soluble in the solvent and the polymer is insoluble in the non-solvent. The separated layer (d1, d2), an article comprising the separated layer, and a use of the treatment solution to separate the first layer from the second layer in the multilayer structure are also disclosed.

IPC Classes  ?

• B29B 17/02 - Separating plastics from other materials
• C08J 11/00 - Recovery or working-up of waste materials
• B29B 17/04 - Disintegrating plastics
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions
• C08J 11/08 - Recovery or working-up of waste materials of polymers without chemical reactions using selective solvents for polymer components

Abstract

The present invention relates to methods of preparing fluorescent labelled polymers, as well as labelled polymers prepared thereby. The fluorescent labelling can be carried out using carbon nanodots derived from natural resources such as fruit peels and plant extracts, and from recycled sources such as recovered raw materials from plastic waste. The labelled polymers can be easily identified and separated from mixed plastic wastes. In aspects, the fluorescent labelling can be used to estimate the amount of the labelled polymer, providing an indication of natural/recycled content, and facilitating its use in compliance methodologies.

IPC Classes  ?

• C09K 11/65 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing carbon

Goods & Services

Business consultancy and business management consultancy in the fields of learning and technology. Educational and training services; educational and training services relating to learning and technology; research services in education, training and learning; research services in learning designed to assist businesses in the evolving future of work and learning; industry led collaborative research for the purpose of understanding learning to enhance education in schools, colleges and the workplace; advisory services relating to industry led collaborative research for the purposes of understanding learning through technology to enhance education in schools, colleges and the workplace. Research in the field of communication technology for learning and teaching purposes; research in the field of information technology for learning and teaching purposes; research in the field of learning technology; research in the field of learning technology to enhance learning, teaching and assessment in all fields of education in schools, colleges and the workplace; industry led collaborative research for the purpose of understanding technology to enhance education in schools, colleges and the workplace; design of learning technology infrastructures for others; consultancy services relating to communication technology for the purpose of learning; consultancy services relating to information technology for learning purposes; consultancy services relating to learning technology; research services in technology designed to assist businesses in the evolving future of work and learning; advice in the field of communication technology for learning and teaching purposes; advice in the field of information technology for learning and teaching purposes; advice in the field of learning technology; advisory services relating to communication technology for the purpose of learning; advisory services relating to information technology for learning purposes; advisory services relating to learning technology to enhance learning, teaching and assessment in all fields of education in schools, colleges and the workplace.

Goods & Services

Business consultancy and business management consultancy in the fields of learning and technology. Educational and training services; educational and training services relating to learning and technology; research services in education, training and learning; research services in learning designed to assist businesses in the evolving future of work and learning; industry led collaborative research for the purpose of understanding learning to enhance education in schools, colleges and the workplace; advisory services relating to industry led collaborative research for the purposes of understanding learning through technology to enhance education in schools, colleges and the workplace. Research in the field of communication technology for learning and teaching purposes; research in the field of information technology for learning and teaching purposes; research in the field of learning technology; research in the field of learning technology to enhance learning, teaching and assessment in all fields of education in schools, colleges and the workplace; industry led collaborative research for the purpose of understanding technology to enhance education in schools, colleges and the workplace; design of learning technology infrastructures for others; consultancy services relating to communication technology for the purpose of learning; consultancy services relating to information technology for learning purposes; consultancy services relating to learning technology; research services in technology designed to assist businesses in the evolving future of work and learning; advice in the field of communication technology for learning and teaching purposes; advice in the field of information technology for learning and teaching purposes; advice in the field of learning technology; advisory services relating to communication technology for the purpose of learning; advisory services relating to information technology for learning purposes; advisory services relating to learning technology to enhance learning, teaching and assessment in all fields of education in schools, colleges and the workplace.

Abstract

A method for measuring an electron signal or an electron induced signal may be provided. The method may include providing a threshold number of events or a threshold event rate for a pixel on a detector. The method may include collecting from the detector the threshold number of events or determining that the threshold event rate is achieved, wherein a signal at the detector is an electron signal or an electron induced signal from a sample. The method may include modulating an intensity of an electron source directed to the sample in response.

IPC Classes  ?

• H01J 37/28 - Electron or ion microscopesElectron- or ion-diffraction tubes with scanning beams
• H01J 37/244 - DetectorsAssociated components or circuits therefor
• H01J 37/22 - Optical or photographic arrangements associated with the tube
• H01J 37/147 - Arrangements for directing or deflecting the discharge along a desired path

Abstract

A device for measuring finger dexterity, comprising a thumb portion configured to be releasably secured to a thumb, a finger portion configured to be releasably secured to an finger, wherein the finger portion and the thumb portion are connected by a flexible connector; a first rotatable element; a rotation sensor configured to sense rotation of the rotatable element, a microprocessor, wherein the microprocessor is in communication with the rotation sensor, and a transmitter configured for wireless communication with a computing device, wherein the rotatable element is configured to rotate when the finger portion and thumb portion move relative to each other, and wherein the microprocessor is configured to generate rotation data in response to rotation of the rotatable element, wherein the transmitter is configured to transmit the rotation data to the computing device.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention concerns a method for separating at least one rare earth element from a solution containing said at least one rare earth element and optionally at least one further magnetic element, the method comprising the following steps a) applying to the solution a non-uniform magnetic field, whereby creating within the solution at least one first zone and at least one second zone having a different magnetic field value, the application of the non-uniform magnetic field value inducing concentrating said at least one rare earth element in the first zone and concentrating said optional at least one further magnetic element in the second zone, b) increasing the pH of the solution in the first zone, to precipitate said at least one rare earth element, or in the second zone to precipitate said optional at least one further magnetic element, and c) recovering the precipitate.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals

Abstract

A composition comprising a polymer and a salt of a pharmaceutical compound, wherein the salt is an ionic liquid is described. A solid dosage form comprising such a composition, and a method of preparing the composition are also described.

IPC Classes  ?

• A61K 31/4164 - 1,3-Diazoles
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline

Abstract

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is selected from O or S; R1 is selected from hydrogen or methyl; Z is CR2R3, wherein R2 and R3 are each independently selected from hydrogen and (1-5C)alkyl, or R2 and R3 are taken together with the carbon atom to which they are attached to form a cyclopropyl or cyclobutyl ring; Z1 is selected from CR4R5, O, S, C(O) or NR6, wherein R4 and R5 are each independently selected from hydrogen, OH, (1-5C)alkyl and phenyl, or R4 and R5 are taken together with the carbon atom to which they are attached to form a cyclopropyl ring, and R6 is selected from hydrogen and (1-5C)alkyl, provided that one, but not both, of Z and Z1 is CH2. The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is selected from O or S; R1 is selected from hydrogen or methyl; Z is CR2R3, wherein R2 and R3 are each independently selected from hydrogen and (1-5C)alkyl, or R2 and R3 are taken together with the carbon atom to which they are attached to form a cyclopropyl or cyclobutyl ring; Z1 is selected from CR4R5, O, S, C(O) or NR6, wherein R4 and R5 are each independently selected from hydrogen, OH, (1-5C)alkyl and phenyl, or R4 and R5 are taken together with the carbon atom to which they are attached to form a cyclopropyl ring, and R6 is selected from hydrogen and (1-5C)alkyl, provided that one, but not both, of Z and Z1 is CH2.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention provides a compound of formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is O; bond a is a single or double bond; x is 1 when a is a single bond and x is 0 when a is a double bond; R1 is selected from hydrogen and methyl; R2 (when present) is selected from hydrogen and methyl; R3 is selected from hydrogen, (1-6C)alkyl and (1-6C)alkyl-phenyl, wherein said phenyl is optionally substituted by one or more (for example 1 to 3) substituents each independently selected from hydroxy, (1-6C)alkoxy, (1-6C)alkyl and halo (such as chloro and fluoro). The present invention provides a compound of formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is O; bond a is a single or double bond; x is 1 when a is a single bond and x is 0 when a is a double bond; R1 is selected from hydrogen and methyl; R2 (when present) is selected from hydrogen and methyl; R3 is selected from hydrogen, (1-6C)alkyl and (1-6C)alkyl-phenyl, wherein said phenyl is optionally substituted by one or more (for example 1 to 3) substituents each independently selected from hydroxy, (1-6C)alkoxy, (1-6C)alkyl and halo (such as chloro and fluoro).

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to methods of preparing nanowire networks, as well as to nanowire networks prepared thereby. The method comprises (a) providing a substrate coated with a film of a first polymer; (b) depositing nanofibers of a second polymer onto the film to form a patterned layer comprising a nanofibre network structure; (c) depositing a layer of a first metal onto the patterned layer; (d) performing a solvent development step to selectively remove the nanofibers leaving a negative pattern exposing the first polymer film; (e) performing an etching step to remove the exposed polymer film; (f) depositing a second metal or oxide thereof onto the negative pattern to form a tem plated nanowire network; and (g) performing a lift-off step to expose the nanowire network.

IPC Classes  ?

• C23C 14/04 - Coating on selected surface areas, e.g. using masks
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• C23C 14/30 - Vacuum evaporation by wave energy or particle radiation by electron bombardment
• C23C 14/20 - Metallic material, boron or silicon on organic substrates

Abstract

A modular adsorber bed for fitting to a vacuum chamber for use in a vacuum temperature swing direct air capture process for extracting carbon dioxide from atmospheric air. The modular adsorber arrangement comprises a plurality of adsorber cartridges arrangeable in an axially parallel array. Each adsorber cartridge comprises a hollow cylinder containing adsorber held in place between an outer gas permeable tube and an inner gas permeable tube, said inner gas permeable tube forming an axially disposed void within the cartridge, wherein, in use, each cartridge is configured to receive airflow from which to adsorb carbon dioxide in a radial direction through the adsorber towards the axially disposed void or in a radial direction through the adsorber away from the axially disposed void.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• F24F 8/00 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying

Abstract

A modular adsorber bed for fitting to a vacuum chamber for use in a vacuum temperature swing direct air capture process for extracting carbon dioxide from atmospheric air. The modular adsorber arrangement comprises a plurality of adsorber cartridges arrangeable in an axially parallel array. Each adsorber cartridge comprises a hollow cylinder containing adsorber held in place between an outer gas permeable tube and an inner gas permeable tube, said inner gas permeable tube forming an axially disposed void within the cartridge, wherein, in use, each cartridge is configured to receive airflow from which to adsorb carbon dioxide in a radial direction through the adsorber towards the axially disposed void or in a radial direction through the adsorber away from the axially disposed void.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• F24F 8/00 - Treatment, e.g. purification, of air supplied to human living or working spaces otherwise than by heating, cooling, humidifying or drying

Abstract

A fixation device for fastening to a native heart valve having native valve leaflets, the fixation device comprising: (a) a device body, and (b) at least one clamp on the device body, the clamp for engaging and holding a native valve leaflet, the clamp comprising at least one moveable jaw, the moveable jaw having thereon at least one gripping element which is moveable relative to the moveable jaw between a native valve leaflet gripping configuration of the moveable jaw where the gripping element is arranged to grip a native valve leaflet and a passive configuration of the moveable jaw where the gripping element is arranged so that it cannot grip a native valve leaflet. This provides a device that can be repositioned during a medical procedure.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

A fixation device for fastening to a native heart valve having native valve leaflets, the fixation device comprising: (a) a device body, and (b) at least one clamp on the device body, the clamp for engaging and holding a native valve leaflet, the clamp comprising at least one moveable jaw, the moveable jaw having thereon at least one gripping element which is moveable relative to the moveable jaw between a native valve leaflet gripping configuration of the moveable jaw where the gripping element is arranged to grip a native valve leaflet and a passive configuration of the moveable jaw where the gripping element is arranged so that it cannot grip a native valve leaflet. This provides a device that can be repositioned during a medical procedure.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

Provided is a unit dose of recombinant adeno-associated virus (AAV) particles for expression of matrix metalloproteinase 3 (MMP-3). Further provided is a unit dose of recombinant MMP-3. Also provided are methods of use thereof, e.g., in transducing the corneal endothelium of a subject; reducing intraocular pressure in an eye of a subject; treating and/or preventing elevated intraocular pressure in a subject; and treating and/or preventing glaucoma in a subject. Subjects include primates.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

A catheter-based ultrasound imaging system configured to provide a full circumferential 360-degree view around an intra-vascular/intra-cardiac imaging-catheter-head by generating a three-dimensional view of the tissue surrounding the imaging-head over time. The ultrasound imaging system can also provide tissue-state mapping capability. The evaluation of the vasculature and tissue characteristics include path and depth of lesions during cardiac-interventions such as ablation. The ultrasound imaging system comprises a catheter with a static or rotating sensor array tip supporting continuous circumferential rotation around its axis, connected to an ultrasound module and respective processing machinery allowing ultrafast imaging and a rotary motor that translates radial movements around a longitudinal catheter axis through a rotary torque transmitting part to rotate the sensor array-tip. This allows the capture and reconstruction of information of the vasculature including tissue structure around the catheter tip for generation of the three-dimensional view over time.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications
• A61B 8/14 - Echo-tomography
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/14 - Probes or electrodes therefor
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• G06T 15/08 - Volume rendering
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a material loaded with one or more drugs comprising mesoporous silica nanoparticles (MSNs) functionalised with polyethylene glycol (PEG) and a hydrogel formed in situ, especially hyaluronic acid (HA) or chitosan (CS). The invention also relates to the use of said material for controlled drug release.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 35/00 - Antineoplastic agents
• C01B 33/18 - Preparation of finely divided silica neither in sol nor in gel formAfter-treatment thereof
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

A method (300) of generating a virtual reality environment comprises obtaining (302) depth data of at least a part of a real scene using one or more sensors (102). The method comprises generating (304) a virtual environment by generating a three-dimensional virtual representation of the at least a part of the real scene using the obtained depth data. The method further comprises displaying (306) the generated virtual representation on at least one display device (108).

IPC Classes  ?

• G06T 7/70 - Determining position or orientation of objects or cameras
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06T 19/00 - Manipulating 3D models or images for computer graphics
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Surgical devices and systems are provided for performing wound closure. For example, a wound closure member is provided with an anchor, a spring member, and a body extending therebetween. The wound closure member is configured to apply an adjustable closure force to tissue to close a wound. Delivery instruments are additionally provided.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials

Goods & Services

Education services; training services; sports training; physical fitness consultation; physical fitness education services; physical fitness training services; personal fitness training services; exercise training services; operating physical fitness training; providing fitness and exercise facilities. Healthcare services; medical testing for fitness evaluation; fitness testing; health counselling; medical counselling; nutritional counselling; psychological counselling; mental health counselling; mental health services; mental health screening services; personality testing (mental health services); personal assessment services (mental health services).

Abstract

The invention relates to a method of immunotherapy for prevention or treatment of cancer in a subject, the method comprising the administration of an adjuvant, or administration of an adjuvant in combination with a tumour antigen, to the subject, wherein the adjuvant comprises polyglucosamine or acetylated polyglucosamine that comprises no more than 10% N-acetyl-D-glucosamine groups, and wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of two or more. The invention relates to a method of immunotherapy for solid-tumour cancer in a subject, the method comprising the administration of polyglucosamine or chitosan into the subject, wherein the administration is intratumoral and/or peritumoral.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

A system for providing heat energy to a direct air carbon dioxide capture process. The system comprises a heat source, coupled via a first thermal transfer circuit to an input of a heat pump, said system further comprising a direct air carbon dioxide capture process apparatus for performing a direct air carbon dioxide capture process coupled to an output of the heat pump via a second thermal transfer circuit. The heat source is a computing data centre, and in use, low grade waste heat energy from the computing data centre is transferred via the first thermal transfer circuit to the heat pump which generates higher grade heat energy which is then transferred from the heat pump to the direct air carbon dioxide capture process apparatus via the second thermal transfer circuit for performing the direct air carbon dioxide capture process. The direct air carbon dioxide capture process is one of a temperature swing adsorption carbon dioxide capture process or a vacuum temperature swing adsorption carbon dioxide capture process.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents

Abstract

A device (100) for measuring ocular microtremor (OMT) of a patient's eye, comprises a light source (10) for illuminating a target area of the eye with a light beam. The device also comprises a detector (20) arranged to detect scattered light from the interaction of the light beam with the target area of the eye. The device further comprises a focusing lens (30) arranged to collect the scattered light for the detector, and a port in a wall of the device through which the light beam can exit the device and/or through which the scattered light can enter the device. The device is configured to stabilise and/or support the device on or against a patients head. A method of measuring microtremor of an eye is also provided.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement

Abstract

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• A61P 17/00 - Drugs for dermatological disorders
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 495/04 - Ortho-condensed systems
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 277/36 - Sulfur atoms
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 487/04 - Ortho-condensed systems
• C07D 215/36 - Sulfur atoms
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 3/00 - Drugs for disorders of the metabolism
• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 221/18 - Ring systems of four or more rings
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 333/34 - Sulfur atoms
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 35/00 - Antineoplastic agents
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 5/00 - Drugs for disorders of the endocrine system
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 307/64 - Sulfur atoms
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• C07D 333/52 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 495/06 - Peri-condensed systems
• C07D 217/24 - Oxygen atoms
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 231/18 - One oxygen or sulfur atom
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 493/04 - Ortho-condensed systems
• C07D 207/38 - 2-Pyrrolones
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 498/04 - Ortho-condensed systems

Abstract

A composition comprising a polymer and a salt of a pharmaceutical compound, wherein the salt is an ionic liquid is described. A solid dosage form comprising such a composition, and a method of preparing the composition are also described.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/37 - Coumarins, e.g. psoralen
• C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3

Abstract

The present invention provides a compound of formula (I), or pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is O; bond a is a single or double bond; x is 1 when a is a single bond and x is 0 when a is a double bond; R1 is selected from hydrogen and methyl; R2 (when present) is selected from hydrogen and methyl; R3 is selected from hydrogen, (1-6C)alkyl and (1-6C)alkyl-phenyl, wherein said phenyl is optionally substituted by one or more (for example 1 to 3) substituents each independently selected from hydroxy, (1-6C)alkoxy, (1-6C)alkyl and halo (such as chloro and fluoro).

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 487/04 - Ortho-condensed systems

Abstract

1233 is selected from hydrogen, (1-6C)alkyl and (1-6C)alkyl-phenyl, wherein said phenyl is optionally substituted by one or more (for example 1 to 3) substituents each independently selected from hydroxy, (1-6C)alkoxy, (1-6C)alkyl and halo (such as chloro and fluoro).

IPC Classes  ?

• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is selected from C or N; X is selected from O or S; R1is selected from hydrogen or methyl; Z is CR2R3, wherein R2and R3are each independently selected from hydrogen and (1-5C)alkyl, or R2and R3are taken together with the carbon atom to which they are attached to form a cyclopropyl or cyclobutyl ring; Z1is selected from CR4R5, O, S, C(O) or NR6, wherein R4and R5are each independently selected from hydrogen, OH, (1-5C)alkyl and phenyl, or R4and R5are taken together with the carbon atom to which they are attached to form a cyclopropyl ring, and R6is selected from hydrogen and (1-5C)alkyl, provided that one, but not both, of Z and Z122.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Goods & Services

Sensitised coatings; Hydrogel polymer coatings; Liquid coatings [chemical]; Unsaturated polyester resin based coatings; Polyurethane coatings [other than paints]; Polymer coatings [other than paints]; Coating agents [chemicals], other than paint; Coating compositions [chemicals], other than paint; Surface coating compositions [chemicals], other than paints; Chemical products for the manufacture of protective coatings; Coating compositions for protection against the effects of encrustation; Coating compositions for protection against the effects of incrustation; Water resistant protective surface coatings [chemical, other than paints]; Unprocessed synthetic resins for powder coatings in industrial applications; Coating compositions [not paint] for protection against the effects of water; Light sensitive organic coating compounds for application to substrates by electrodeposition; Wear resistant ceramic compounds; Weather resistant coatings [chemical, other than paints]. Powder coatings; Resinous coatings; Epoxy coatings; Organometallic coating materials; Epoxy resin coatings; Textured coatings [paints]; Acrylic coatings [paints]; Polyurethane coatings [paints]; Spray coatings [paints]; Conversion coatings [paints]; Transparent coating materials [paints]; Surface coating compositions [paints]; Electrophoretic coating materials [paints]; Conversion coating compositions [paints]; Resins for coating purposes; Protective coating compositions [paints]; Transparent coating compositions [paints]; Protective surface coatings [paints]; Non-metallic coating materials [paints]; Coating preparations for protection against wear; Coating preparations for protection against friction; Stabilising preparations in the nature of coatings; Surface coatings in the nature of paint; Coating compositions in the form of oils; Coating compositions in the nature of oils; Powder coatings for application by spray; Protective coating materials in the nature of paint; Protective coatings in the nature of paints and containing abrasive particles; Coatings in the nature of electrophoretic materials [paints]; Acrylic protective coatings [in the nature of paint]; Corrosion inhibitors in the nature of a coating; Preparations for coating surfaces to protect against abrasion; Heat resistant coatings in the nature of paint; Coatings in the nature of electrolytic materials [paints]; Coatings for protection against the corrosive effect of acids; Liquid plastics surface coatings [paints] for protection against moisture; Preparations for use as waterproofing coatings on the surfaces of structures [paints]; Protective acrylic coatings in the form of paints [other than for insulating purposes]; Corrosion resistant coatings; Corrosion resistant paint containing phenol; Corrosion resistant coatings containing phenol. Application of surface coatings. Treatment of hazardous waste by encapsulation; Electro-phoretic coating; Titanium nitride coating; Application of coatings using vacuum deposition techniques; Application of coatings using chemical vapor deposition techniques; Application of coatings using physical vapor deposition techniques; Application of coatings using thermal plasma spraying techniques; Application of wear resistant coatings by electrolytic processes; Application of wear resistant coatings by autocatalytic processes; Application of wear resistant coatings to engineering components. Development of coatings for non-metals.

Abstract

The present invention relates to methods of preparing nanowire networks, as well as to nanowire networks prepared thereby. The method comprises (a) providing a substrate coated with a film of a first polymer; (b) depositing nanofibers of a second polymer onto the film to form a patterned layer comprising a nanofibre network structure; (c) depositing a layer of a first metal onto the patterned layer; (d) performing a solvent development step to selectively remove the nanofibers leaving a negative pattern exposing the first polymer film; (e) performing an etching step to remove the exposed polymer film; (f) depositing a second metal or oxide thereof onto the negative pattern to form a templated nanowire network; and (g) performing a lift-off step to expose the nanowire network.

IPC Classes  ?

• H01L 31/0224 - Electrodes
• H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
• H01L 33/42 - Transparent materials
• H01L 51/44 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation - Details of devices

Abstract

A liquid cooled thermal heat sink is provided. A plurality of jet orifices provide an exit for pressurised liquid to exit a plenum chamber and impinge on a thermal surface whereby they effect a cooling of the thermal surface, the heated liquid being transferred through an exit channel to dissipate heat away from the thermal surface.

IPC Classes  ?

• H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids
• F28D 3/02 - Heat-exchange apparatus having stationary conduit assemblies for one heat-exchange medium only, the media being in contact with different sides of the conduit wall, in which the other heat-exchange medium flows in a continuous film, or trickles freely, over the conduits with tubular conduits

Abstract

The invention relates to a luminescence-based colorimetric sensor formulation and method of use thereof. The sensor formulation can be used to assess oxygen concentration, particularly in controlled oxygen atmospheres such as food packaging. In embodiments, the invention also relates to sensor-containing laminate films for food packaging, and methods of their preparation.

IPC Classes  ?

• C09D 11/50 - Sympathetic, colour-changing or similar inks
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 21/29 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
• G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators

Abstract

The present application relates to an adjuvant which is suitable to be used in vaccines or other immunogenic compositions. Specifically, the adjuvant promotes the induction of interleukin-1 (IL-1), type 1 interferons (IFNs), such as IFNα, and IFNβ, type 2 interferons, such as IFNγ and/or tumour necrosis factor (TNF) response, such as TNFα, and elicits or enhances an immune response, preferably in neonatal, juvenile or paediatric animal and/or human populations.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/04 - Immunostimulants

Abstract

A catheter-based ultrasound imaging system configured to provide a full circumferential 360-degree view around an intra-vascular/intra-cardiac imaging-catheter-head by generating a three-dimensional view of the tissue surrounding the imaging-head over time. The ultrasound imaging system can also provide tissue-state mapping capability. The evaluation of the vasculature and tissue characteristics include path and depth of lesions during cardiac-interventions such as ablation. The ultrasound imaging system comprises a catheter with a static or rotating sensor array tip supporting continuous circumferential rotation around its axis, connected to an ultrasound module and respective processing machinery allowing ultrafast imaging and a rotary motor that translates radial movements around a longitudinal catheter axis through a rotary torque transmitting part to rotate the sensor array-tip. This allows the capture and reconstruction of information of the vasculature including tissue structure around the catheter tip for generation of the three-dimensional view over time.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 18/14 - Probes or electrodes therefor
• A61B 8/14 - Echo-tomography
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• G06T 15/08 - Volume rendering
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The invention provides a method and system for Dynamic Bandwidth Assignment (DBA) Virtualization in a Passive Optical Network, comprising an Optical Line Termination (OLT) point and a plurality of Optical Network Units (ONU) and a plurality of Virtual Network Units (VNO), wherein each VNO is configured with a virtual Dynamic Bandwidth Assignment module to schedule a bandwidth assignment independently of the other VNOs and using a merging engine to implement a detailed bandwidth scheduling allocation over the Passive Optical Network.

IPC Classes  ?

• H04Q 11/00 - Selecting arrangements for multiplex systems
• H04L 12/927 - Allocation of resources based on type of traffic, QoS or priority

Abstract

Compounds and pharmaceutical compositions for use in the treatment of psoriasis are disclosed. Preferred compounds have demonstrated efficacy in reducing skin scaling, erythema and skin thickness in the mouse model of Aldara-induced psoriasis.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61P 17/06 - Antipsoriatics
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

e.g.e.g., in transducing the corneal endothelium of a subject; reducing intraocular pressure in an eye of a subject; treating and/or preventing elevated intraocular pressure in a subject; and treating and/or preventing glaucoma in a subject. Subjects include primates.

IPC Classes  ?

• C12N 15/864 - Parvoviral vectors
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

A catheter-based ultrasound imaging system configured to provide a full circumferential 360-degree view around an intra-vascular/intra-cardiac imaging-catheter-head by generating a three-dimensional view of the tissue surrounding the imaging-head over time. The ultrasound imaging system can also provide tissue-state mapping capability. The evaluation of the vasculature and tissue characteristics include path and depth of lesions during cardiac-interventions such as ablation. The ultrasound imaging system comprises a catheter with a static or rotating sensor array tip supporting continuous circumferential rotation around its axis, connected to an ultrasound module and respective processing machinery allowing ultrafast imaging and a rotary motor that translates radial movements around a longitudinal catheter axis through a rotary torque transmitting part to rotate the sensor array-tip. This allows the capture and reconstruction of information of the vasculature including tissue structure around the catheter tip for generation of the three-dimensional view over time.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 8/14 - Echo-tomography
• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• G06T 15/08 - Volume rendering
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Provided herein is a composition comprising nanoparticles, wherein the nanoparticles comprise chitosan or a derivative thereof and clathrin or a derivative thereof. The chitosan or derivative thereof may be conjugated to clathrin or a derivative thereof. Also provided are pharmaceutical compositions comprising nanoparticles, and therapeutic uses thereof for delivering active agents across the blood- brain-barrier and treating neurological disease. Methods of producing compositions comprising nanoparticles are also described.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention describes compounds of formula (I) Y is C, N or S. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases.

IPC Classes  ?

• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 487/04 - Ortho-condensed systems
• A61P 37/02 - Immunomodulators

Abstract

The invention provides a system and method of identifying when a message is received at a control station from at least one device in a network having a plurality of devices, said method comprising the steps of receiving at the control station a low bandwidth signal from at least one device; obtaining a coarse timestamp estimate of when said low bandwidth signal is received by correlating with a pre-programmed signal template; generating a higher resolution correlation estimate by phase shifting the pre-programmed signal template and repeating the correlation; and detecting where the correlation is above a preselected value; and applying a curve fitting function about the higher resolution correlation estimate to obtain an accurate timestamp when the message was received.

IPC Classes  ?

• H04W 56/00 - Synchronisation arrangements
• H04L 29/08 - Transmission control procedure, e.g. data link level control procedure
• H04W 84/18 - Self-organising networks, e.g. ad hoc networks or sensor networks

Abstract

Surgical devices and systems are provided for performing wound closure. For example, a wound closure member is provided with an anchor, a spring member, and a body extending therebetween. The wound closure member is configured to apply an adjustable closure force to tissue to close a wound. Delivery instruments are additionally provided.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials
• A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines

Abstract

Surgical devices and systems are provided for performing wound closure. For example, a wound closure member is provided with an anchor, a spring member, and a body extending therebetween. The wound closure member is configured to apply an adjustable closure force to tissue to close a wound. Delivery instruments are additionally provided.

IPC Classes  ?

• A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials

Abstract

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: 2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 49/00 - Preparations for testing in vivo
• C07C 311/47 - Y being a hetero atom
• C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 235/26 - Oxygen atoms
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 295/26 - Sulfur atoms
• C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
• C07D 317/66 - Nitrogen atoms not forming part of a nitro radical
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

An adsorbent media comprising a plurality of pellets of adsorbent material. The pellets of adsorbent material comprise up to 1.5wt% of an organic binder. The pellets of adsorbent material can be sub-millimetre. The pellets of adsorbent material may show comparable or improved performance to the adsorbent material in powder form in gas separation and capture processes. The adsorbent media may therefore be used in an industrial process for gas capture and separation. The adsorbent media also comprises low concentrations of binder. Therefore the adsorbent media may be considered as environmentally friendly. A method for producing the adsorbent media comprising a plurality of pellets of adsorbent material is also provided.

IPC Classes  ?

• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/16 - Alumino-silicates
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01J 2/20 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by expressing the material, e.g. through sieves and fragmenting the extruded length

Abstract

A method is disclosed for separating compressed dry air to provide carbon dioxide and reduced-carbon dioxide compressed dry air. The method comprises providing a source of compressed dry air and admitting compressed dry air into a first chamber containing a carbon dioxide-adsorbent material at a first temperature. The carbon dioxide-adsorbent material adsorbs carbon dioxide from the compressed dry air to form reduced-carbon dioxide compressed dry air, which is allowed to pass out of the first chamber. The first chamber is closed to the source of compressed dry air. Then the carbon dioxide-adsorbent material is heated to a second temperature. This releases carbon dioxide from the carbon dioxide- adsorbent material, which carbon dioxide is removed from the first chamber. The method may be low cost and low energy, and may be easily integrated into existing compressed dry air systems. A carbon dioxide capture unit and a compressed dry air production system for separating compressed dry air to provide carbon dioxide and reduced-carbon dioxide compressed dry air are also described.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01D 53/053 - Pressure swing adsorption with storage or buffer vessel

Abstract

3 inhibition and the stimulation of insulin secretion.

IPC Classes  ?

• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 495/04 - Ortho-condensed systems
• C07D 207/38 - 2-Pyrrolones
• C07D 217/24 - Oxygen atoms
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides a method of using Raman spectroscopy for identification of low grade cervical cytology cases likely to progress to high grade/cancer. The Applicant has found that high quality Raman spectra can be successfully acquired from morphologically normal appearing cells from negative, LSIL and HSIL Thinprep® specimens and different grades of cervical pre-cancer can be separated with good sensitivities and specificities. Raman spectroscopy can further identify different categories of the LSIL cases i.e., whether they are likely to regress to negative or progress to HSIL cytology.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• G01J 3/44 - Raman spectrometryScattering spectrometry
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to a luminescence-based colorimetric sensor formulation and method of use thereof. The sensor formulation can be used to assess oxygen concentration, particularly in controlled oxygen atmospheres such as food packaging. In embodiments, the invention also relates to sensor-containing laminate films for food packaging, and methods of their preparation.

IPC Classes  ?

• C09D 11/50 - Sympathetic, colour-changing or similar inks
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/07 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials having chemically-interreactive components, e.g. reactive chemiluminescent compositions
• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators

Abstract

The invention relates to a luminescence-based colorimetric sensor formulation and method of use thereof. The sensor formulation can be used to assess oxygen concentration, particularly in controlled oxygen atmospheres such as food packaging. In embodiments, the invention also relates to sensor-containing laminate films for food packaging, and methods of their preparation.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• G01P 5/00 - Measuring speed of fluids, e.g. of air streamMeasuring speed of bodies relative to fluids, e.g. of ship, of aircraft
• G01K 11/20 - Measuring temperature based on physical or chemical changes not covered by group , , , or using thermoluminescent materials
• G01K 13/02 - Thermometers specially adapted for specific purposes for measuring temperature of moving fluids or granular materials capable of flow
• C09D 11/50 - Sympathetic, colour-changing or similar inks
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09K 11/07 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials having chemically-interreactive components, e.g. reactive chemiluminescent compositions

Abstract

A device (100) for measuring ocular microtremor (OMT) of a patient's eye, comprises a light source (10) for illuminating a target area of the eye with a light beam. The device also comprises a detector (20) arranged to detect scattered light from the interaction of the light beam with the target area of the eye. The device further comprises a focusing lens (30) arranged to collect the scattered light for the detector, and a port in a wall of the device through which the light beam can exit the device and/or through which the scattered light can enter the device. The device is configured to stabilise and/or support the device on or against a patient's head. A method of measuring microtremor of an eye is also provided.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

A device (100) for measuring ocular microtremor (OMT) of a patient's eye, comprises a light source (10) for illuminating a target area of the eye with a light beam. The device also comprises a detector (20) arranged to detect scattered light from the interaction of the light beam with the target area of the eye. The device further comprises a focusing lens (30) arranged to collect the scattered light for the detector, and a port in a wall of the device through which the light beam can exit the device and/or through which the scattered light can enter the device. The device is configured to stabilise and/or support the device on or against a patient's head. A method of measuring microtremor of an eye is also provided.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

A liquid cooled thermal heat sink is provided. A plurality of jet orifices provide an exit for pressurised liquid to exit a plenum chamber and impinge on a thermal surface whereby they effect a cooling of the thermal surface, the heated liquid being transferred through an exit channel to dissipate heat away from the thermal surface.

IPC Classes  ?

• H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

A liquid cooled server module comprising side walls defining an enclosure volume within the module within which electronic components are packaged is described.

IPC Classes  ?

• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

The present application relates to an adjuvant which is suitable to be used in vaccines or other immunogenic compositions. Specifically, the adjuvant promotes the induction of interleukin-1 (IL-1), type 1 interferons (IFNs), such as IFNα, and IFNβ, type 2 interferons, such as IFNγ and/or tumour necrosis factor (TNF) response, such as TNFα, and elicits or enhances an immune response, preferably in neonatal, juvenile or paediatric animal and/or human populations.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 37/04 - Immunostimulants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• A61P 5/00 - Drugs for disorders of the endocrine system
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C07D 215/36 - Sulfur atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems
• C07D 493/04 - Ortho-condensed systems
• A61P 17/00 - Drugs for dermatological disorders
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 217/24 - Oxygen atoms
• C07D 495/04 - Ortho-condensed systems
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 221/18 - Ring systems of four or more rings
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• C07D 333/52 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 307/64 - Sulfur atoms
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 277/36 - Sulfur atoms
• C07D 498/04 - Ortho-condensed systems
• C07D 207/38 - 2-Pyrrolones
• C07D 495/06 - Peri-condensed systems
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 231/18 - One oxygen or sulfur atom
• C07D 333/34 - Sulfur atoms
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Goods & Services

Educational and training services, providing instruction and training at undergraduate, graduate, and post graduate level; organizing and conducting educational classes, lectures, examinations, seminars, workshops and symposia at undergraduate, graduate, and post graduate level; organising and arranging exhibitions for entertainment purposes; organising live exhibitions and conferences in the fields of education, culture, sports and entertainment for non-business and non-commercial purposes; publication of books and texts; non-downloadable electronic publications, books, booklets and newsletters, brochures, pamphlets, periodicals, catalogues and magazines in the field of education and training; educational entertainment services and information, providing motivational and educational speakers; providing museum facilities; providing information on entertainment events held at sports facilities; providing facilities for educational training and conventions; organising sports competitions; providing sports facilities; providing recreation facilities; providing on-line training and education at undergraduate, graduate and post graduate level from a computer database or from facilities provided on the Internet and other similar information networks; providing on-line continuing professional educational lectures, classes, seminars, symposia and workshops at undergraduate, graduate, and post graduate level; advisory, consultancy and information services relating to all of the aforesaid services.

Abstract

A method and system for generating voltage and/or current oscillations in a single magnetic layer is provided. The method comprises applying a direct voltage/current to the layer in a longitudinal direction; and developing a longitudinal voltage between a pair of longitudinal voltage leads and/or a transverse voltage between a pair of transverse voltage leads. The magnetic layer comprises a ferrimagnetic or antiferrimagnetic material having a first and second magnetic sub-lattice, wherein the first sub-lattice is a dominant sub-lattice such that the charge carriers at the Fermi energy originate predominantly from the dominant sub-lattice and the charge carriers at the Fermi energy are spin polarised. In some embodiments, the dominant current carrying sub-lattice may lack inversion symmetry.

IPC Classes  ?

• H01L 43/00 - Devices using galvano-magnetic or similar magnetic effects; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof
• H03B 15/00 - Generation of oscillations using galvano-magnetic devices, e.g. Hall-effect devices, devices using spin transfer effects, devices using giant magnetoresistance, or using super-conductivity effects

Abstract

A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

A heart valve therapeutic device (1) comprises a coaptation assist valve (20) comprising a conduit (2) with an outer surface (3) for coaption with the native leaflets, and a prosthetic flow valve (5) mounted within the conduit (2) to allow one-way flow through the conduit (2). Support for the coaptation assist valve (20) is provided by a support (10) for positioning the conduit (2) across the native leaflets, and connectors (15) attaching the conduit (2) to the support (10).

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

The method comprising providing a plurality of images of a scene captured by a plurality of image capturing devices (101); providing silhouette information of at least one object in the scene (102); generating a point cloud for the scene in 3D space using the plurality of images (103); extracting an object point cloud from the generated point cloud, the object point cloud being a point cloud associated with the at least one object in the scene (104); estimating a 3D shape volume of the at least one object from the silhouette information (105); and combining the object point cloud and the shape volume of the at least one object to generate a three- dimensional model (106). An apparatus for generating a 3D model, and a computer readable medium for generating the 3D model.

IPC Classes  ?

• G06T 7/564 - Depth or shape recovery from multiple images from contours
• G06T 7/593 - Depth or shape recovery from multiple images from stereo images

Abstract

A disposable x-ray side marker (100) comprises a non-metallic material (108) having a sufficiently high linear attenuation coefficient to be radiographically visible. The material (108) may be mouldable, and may be or comprise gypsum. The material (108) may have an average atomic number greater than or equal to 11, and may have a linear attenuation coefficient greater than that of mammalian soft tissue.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• G03B 42/04 - Holders for X-ray films
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

A robot is provided, the robot comprising a body carrying a first drive arrangement, a second drive arrangement and a stabiliser. The robot further comprises actuators operable to cause relative movement of the first drive arrangement, the second drive arrangement and the stabiliser, and to drive the first and the second drive arrangements. The robot is arrangeable in first, second and third configurations each having static stability. In the first configuration, the stabiliser and the first drive arrangement are arranged to contact the ground. In the second configuration, the stabiliser and the second drive arrangement are arranged to contact the ground. In the third configuration, the first and the second drive arrangements are arranged to contact the ground. No other ground contacting point is involved in conferring said static stability in said configurations.

IPC Classes  ?

• B62D 57/024 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members specially adapted for moving on inclined or vertical surfaces
• B62D 57/028 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members having wheels and mechanical legs
• B60B 19/00 - Wheels not otherwise provided for or having characteristics specified in one of the subgroups of this group

Abstract

Apparatus and methods for reducing biofouling in beverage dispensing equipment, such as beer dispensing equipment, are described.

IPC Classes  ?

• C08J 7/12 - Chemical modification
• B08B 17/02 - Preventing deposition of fouling or of dust
• C08G 69/48 - Polymers modified by chemical after-treatment

Abstract

Provided herein are electrospun or electroblown non-woven fiber membranes, methods of making such membranes and lateral flow diagnostic devices comprising such membranes.

IPC Classes  ?

• B01D 71/34 - Polyvinylidene fluoride
• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
• B01D 71/40 - Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
• D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
• D01D 5/00 - Formation of filaments, threads, or the like
• B01D 69/10 - Supported membranesMembrane supports
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/545 - Synthetic resin

Abstract

The present invention relates to magnetic core-shell nanoparticles, as well as to their use in the initiation of redox-triggered polymerisation processes. The invention also relates to a formulation comprising the magnetic core-shell nanoparticles, and particularly an adhesive formulation, as well as to associated methods of controlling the adhesion of at least two adherends utilising the adhesive formulation. Further embodiments of the invention relate to methods of controlling redox-triggered polymerisation processes, and particularly redox radical-triggered adhesive polymerisation.

IPC Classes  ?

• C09J 11/04 - Non-macromolecular additives inorganic
• C09J 11/06 - Non-macromolecular additives organic
• H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties

Abstract

The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation.Pharmaceutical compositions are also enabled herein.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

IPC Classes  ?

• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 207/38 - 2-Pyrrolones
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 307/64 - Sulfur atoms
• C07D 309/04 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Abstract

This invention relates to asingle crystallineorganometal trihalide perovskite film, or a single crystalline metal dihalide film, having a thickness of less than 1µm, wherein the metal is Pb and the halide comprises Br. The invention also relates to a process for preparing thesingle crystalline metal dihalide film, as well as to aprocess for preparing thesingle crystallineorganometal trihalide perovskite film.

IPC Classes  ?

• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/12 - Halides
• C30B 29/54 - Organic compounds
• C30B 29/64 - Flat crystals, e.g. plates, strips or discs
• C30B 31/08 - Diffusion or doping processes for single crystals or homogeneous polycrystalline material with defined structureApparatus therefor by contacting with diffusion material in the gaseous state the diffusion materials being a compound of the elements to be diffused
• H01L 21/00 - Processes or apparatus specially adapted for the manufacture or treatment of semiconductor or solid-state devices, or of parts thereof

Abstract

Compounds and pharmaceutical compositions for use in the treatment of psoriasis are disclosed. Preferred compounds have demonstrated efficacy in reducing skin scaling, erythema and skin thickness in the mouse model of Aldara-induced psoriasis.

IPC Classes  ?

• A61P 17/06 - Antipsoriatics
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides

Abstract

The invention provides a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis, using a molecule capable of acting as substrate for the queuine-insertase enzyme complex.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides a method of using Raman spectroscopy for identification of low grade cervical cytology cases likely to progress to high grade / cancer. The Applicant has found that high quality Raman spectra can be successfully acquired from morphologically normal appearing cells from negative, LSIL and HSIL Thinprep RTM specimens and different grades of cervical pre-cancer can be separated with good sensitivities and specificities. Raman spectroscopy can further identify different categories of the LSIL cases i.e., whether they are likely to regress to negative or progress to HSIL cytology.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 21/65 - Raman scattering
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 307/64 - Sulfur atoms
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 493/04 - Ortho-condensed systems
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 333/34 - Sulfur atoms
• C07D 277/36 - Sulfur atoms
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 231/18 - One oxygen or sulfur atom
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07C 311/60 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
• C07D 333/52 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 495/04 - Ortho-condensed systems
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 487/04 - Ortho-condensed systems
• C07D 215/36 - Sulfur atoms
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 498/04 - Ortho-condensed systems
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 217/24 - Oxygen atoms
• C07D 207/38 - 2-Pyrrolones
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 221/18 - Ring systems of four or more rings
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 495/06 - Peri-condensed systems
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• A61P 35/00 - Antineoplastic agents
• A61P 3/00 - Drugs for disorders of the metabolism
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• A61P 17/00 - Drugs for dermatological disorders
• A61P 5/00 - Drugs for disorders of the endocrine system
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Abstract

A robot is provided, the robot comprising a body carrying a first drive arrangement, a second drive arrangement and a stabiliser. The robot further comprises actuators operable to cause relative movement of the first drive arrangement, the second drive arrangement and the stabiliser, and to drive the first and the second drive arrangements. The robot is arrangeable in first, second and third configurations each having static stability. In the first configuration, the stabiliser and the first drive arrangement are arranged to contact the ground. In the second configuration, the stabiliser and the second drive arrangement are arranged to contact the ground. In the third configuration, the first and the second drive arrangements are arranged to contact the ground. No other ground contacting point is involved in conferring said static stability in said configurations.

IPC Classes  ?

• B62D 57/024 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members specially adapted for moving on inclined or vertical surfaces
• B62D 57/028 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members having wheels and mechanical legs

Abstract

Disclosed are novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases. The present invention describes compounds of formula (I) Y is C, N or S.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

IPC Classes  ?

• C07D 231/18 - One oxygen or sulfur atom
• C07C 307/06 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
• C07C 307/08 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07C 307/10 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
• C07D 295/26 - Sulfur atoms
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided herein are 3-phenyl-7-hydroxy-isocoumarin compounds which are MIF inhibitors; compositions comprising said inhibitors and methods for treating or preventing diseases associated with MIF.

IPC Classes  ?

• C07D 311/76 - Benzo [c] pyrans

Abstract

(E)-2-(2-Quinolin-2-yl-propenyl)-phenol, 2-Quinolin-2-yl-ylethynyl-phenol and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.

IPC Classes  ?

• C07D 215/14 - Radicals substituted by oxygen atoms
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Goods & Services

(1) Educational services, namely, providing classes, seminars and workshops in the fields of science and technology, namely, medical science, environmental science, social science, natural sciences, chemistry, physics, computer technology, structural engineering, mechanical engineering, chemical engineering, geotechnical engineering, electrical engineering and computer engineering, mathematics, computer technology, medical technology and travel technology, industrial design and robotics; providing training in the fields of science and technology, namely, medical science, environmental science, social science, natural sciences, chemistry, physics, computer technology, structural engineering, mechanical engineering, chemical engineering, geotechnical engineering, electrical engineering and computer engineering, mathematics, computer technology, medical technology and travel technology, industrial design and robotics; organizing community sporting and cultural events, namely, visual arts, theatre, dance, music, architecture, film and animation, literature and poetry, photography, sculpture, performance arts and graphic design; arranging and conducting educational colloquiums, conferences, seminars and symposia in the fields of science and technology, namely, medical science, environmental science, social science, natural sciences, chemistry, physics, computer technology, structural engineering, mechanical engineering, chemical engineering, geotechnical engineering, electrical engineering and computer engineering, mathematics, computer technology, medical technology and travel technology, industrial design and robotics; arranging and conducting training and educational workshops in the fields of science and technology, namely, medical science, environmental science, social science, natural sciences, chemistry, physics, computer technology, structural engineering, mechanical engineering, chemical engineering, geotechnical engineering, electrical engineering and computer engineering, mathematics, computer technology, medical technology and travel technology, industrial design and robotics

Abstract

An inflation balloon 1 comprising a compliant balloon wall 3 and a first 5 and second 10 set of non-compliant filamentous members embedded in the balloon wall. The filamentous members are arranged to be slack so as to allow inflation of the inflation balloon, but to restrain the balloon to an expanded diameter when all of the slack has been taken up by expansion of the balloon. The first filamentous members undergoes controlled failure to expand the balloon to a second larger expanded size.

IPC Classes  ?

• A61M 25/10 - Balloon catheters

Abstract

Apparatus and methods for reducing biofouling in drink such as beer dispensing equipment are described.

IPC Classes  ?

• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• B67D 1/07 - Cleaning beverage-dispensing apparatus

Abstract

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• C07D 231/18 - One oxygen or sulfur atom
• C07D 307/64 - Sulfur atoms
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 333/34 - Sulfur atoms
• C07D 277/36 - Sulfur atoms
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07C 311/54 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 207/38 - 2-Pyrrolones
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 495/06 - Peri-condensed systems
• C07D 498/04 - Ortho-condensed systems
• C07D 217/24 - Oxygen atoms
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 17/00 - Drugs for dermatological disorders
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Abstract

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

IPC Classes  ?

• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07C 311/54 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
• C07C 311/56 - Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07D 207/38 - 2-Pyrrolones
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 217/24 - Oxygen atoms
• C07D 231/18 - One oxygen or sulfur atom
• C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 277/36 - Sulfur atoms
• C07D 307/18 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 307/64 - Sulfur atoms
• C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 311/60 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2
• C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
• C07D 333/34 - Sulfur atoms
• C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 495/06 - Peri-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

A modelling system is implemented by a digital processor. The system models fragmentation of spacecraft during the atmospheric re-entry. It predicts propagation of the surviving fragments, given the physical characteristics of the craft and its re-entry trajectory. Fragmentation is modelled by a stick-breaking type of model, an example of which is the Dirichlet model, and this model is tuned using Bayesian processing in order to better fit the data. Such tuning in particularly effective in the invention because much of the available data is in the form of expert opinion. A probability technique such as Bayesian processing quantifies the expert opinion and other non-hard data into the form of a probability distribution. This approach also accommodates the fact that there is much missing data.

IPC Classes  ?

• B64G 7/00 - Simulating cosmonautic conditions, e.g. for conditioning crews
• B64G 99/00 - Subject matter not provided for in other groups of this subclass
• B64G 1/62 - Systems for re-entry into the earth's atmosphereRetarding or landing devices

Abstract

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis.In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for Hypoxanthine- guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases. Preferably the autoimmune disease is multiple sclerosis.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention describes compounds of formula (I)(see formula I)wherein: R1 is selected from H and CH3; R2 is selected from C4H9 alkyl, C6H13 alkyl and C3H6-phenyl, said phenyl optionally substituted by OH or OCH3 ; X is O; andY is N. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention describes compounds of formula (I) (I) Wherein: R1 is selected from H and CH3 R2 is selected from H, C4H9 alkyl, C6H13 alkyl and C3H6-phenyl, said phenyl optionally substituted by OH or OCH3, (1R,2S,5S)-5-methylcyclopent-3-ene-1,2-diol X is O or S Y is C, N or S. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis.In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for Hypoxanthine- guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases. Preferably the autoimmune disease is multiple sclerosis.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 37/00 - Drugs for immunological or allergic disorders